title: Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
abstract: OBJECTIVE
  The aim of this study was to confirm the predictive/prognostic value of the preadjuvant Glasgow Prognostic Score (GPS) and carbohydrate antigen (CA) 19-9 level in pancreatic cancer patients receiving adjuvant gemcitabine (GEM) after surgery.
  
  
  METHODS
  A total of 67 resected pancreatic cancer patients, treated with adjuvant GEM, were included. The GPS and CA19-9 level were calculated prior to administration of adjuvant therapy and were found to correlate with the outcomes and rate of early recurrence.
  
  
  RESULTS
  An elevated preadjuvant GPS or CA19-9 level was significantly associated with a shorter overall survival (OS) (p=0.003 and p<0.001, respectively). Either an elevated GPS or CA19-9 level predicted early recurrence and the combined use of these two factors improved the ability to predict early recurrence, with a specificity and accuracy up to 0.958 and 0.821, respectively.
  
  
  CONCLUSIONS
  Both an elevated preadjuvant GPS and CA19-9 level, when used alone, are significant predictors of poor outcomes in pancreatic cancer patients receiving adjuvant GEM. The combined use of these parameters improves the ability to predict early recurrence in such patients.
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan koji-numata@hotmail.co.jp.
authors.forename: Koji
authors.initials: K
authors.lastname: Numata
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Soichiro
authors.initials: S
authors.lastname: Morinaga
authors.affiliation: Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Katayama
authors.affiliation: Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan.
authors.forename: Sho
authors.initials: S
authors.lastname: Sawazaki
authors.affiliation: Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan.
authors.forename: Masakatsu
authors.initials: M
authors.lastname: Numata
authors.affiliation: Department of Surgery, Fujisawa Shonandai Hospital, Fujisawa, Japan.
authors.forename: Teni
authors.initials: T
authors.lastname: Godai
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Akio
authors.initials: A
authors.lastname: Higuchi
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Asahiku, Yokohama, Japan.
authors.forename: Manabu
authors.initials: M
authors.lastname: Shiozawa
authors.affiliation: Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Rino
authors.affiliation: Department of Surgery, Yokohama City University, Kanazawaku, Yokohama, Japan.
authors.forename: Munetaka
authors.initials: M
authors.lastname: Masuda
authors.affiliation: Department of General Medicine, Chigasaki Chuo Hospital, Chigasaki, Japan.
authors.forename: Makoto
authors.initials: M
authors.lastname: Akaike
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D018395:CA-19-9 Antigen / Q000097:blood*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D018395:CA-19-9 Antigen; D003841:Deoxycytidine; D000093542:Gemcitabine
keywords: Glasgow prognostic score; carbohydrate antigen 19-9; curative surgery; early recurrence; gemcitabine monotherapy; pancreatic cancer